Goodenberger McKinsey L, Thomas Brittany C, Riegert-Johnson Douglas, Boland C Richard, Plon Sharon E, Clendenning Mark, Win Aung Ko, Senter Leigha, Lipkin Steven M, Stadler Zsofia K, Macrae Finlay A, Lynch Henry T, Weitzel Jeffrey N, de la Chapelle Albert, Syngal Sapna, Lynch Patrick, Parry Susan, Jenkins Mark A, Gallinger Steven, Holter Spring, Aronson Melyssa, Newcomb Polly A, Burnett Terrilea, Le Marchand Loïc, Pichurin Pavel, Hampel Heather, Terdiman Jonathan P, Lu Karen H, Thibodeau Stephen, Lindor Noralane M
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Medical Genetics, Mayo Clinic, Jacksonville, Florida, USA.
Genet Med. 2016 Jan;18(1):13-9. doi: 10.1038/gim.2015.27. Epub 2015 Apr 9.
Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.Genet Med 18 1, 13-19.
MLH1、MSH2、MSH6和PMS2的种系突变已被证明会导致林奇综合征。癌症的外显率和肿瘤谱已被反复研究,多个专业学会也针对受影响个体提出了临床管理指南。多项研究表明,与其他错配修复(MMR)基因相比,PMS2突变的单等位基因携带者的外显率有所降低,但临床管理指南在很大程度上对所有MMR基因携带者提出了相同的筛查建议。作者们思考是否有足够的证据来针对PMS2突变携带者提出关于发病年龄和结肠筛查频率的新筛查指南。将已发表的PMS2种系突变报告与作者研究登记处和临床实践中的未发表病例相结合,并探讨了癌症筛查指南的潜在修改。共纳入了来自170个家庭的234名单等位基因PMS2突变携带者。约8%的结直肠癌(CRC)患者在30岁之前被诊断出来,且这些肿瘤均出现在结肠左侧。由于目前尚不清楚在一些携带单等位基因PMS2种系突变的家庭中导致CRC早发的原因,尽管外显率降低,但作者们仍建议不要降低对发现有单等位基因PMS2突变家庭的癌症监测指南标准。《遗传医学》18卷1期,第13 - 19页 。